Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Former SC Johnson Worldwide Chief Technical Officer Joins Double Eagle Holdings Board
5 days 18 minutes ago - PR Newswire via Comtex
PR Newswire
Double Eagle Holdings, Ltd. (Pink Sheets: DEGH) announced today that it has added Dr. Richard Hutchings, the former worldwide Chief Technical Officer at SC Johnson and global R&D Director of many of SC Johnson's most recognizable consumer products, to the company's Board of Directors. Double Eagle Holdings is the parent company of Fuse Science, Inc. (www.fusescience.com), developer of new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.
"The significance of the Fuse Science technology demands proven leadership to drive the company forward, and we are now in the final stages of expanding our board of directors, science team and expert advisory panel through a comprehensive selection process," said Brian Tuffin, the company's President and Chief Operating Officer. "Dr. Hutchings' commitment is a clear sign that we have the ability to attract the world's top consumer products executives and that we are moving aggressively in the right direction."
Hutchings began his professional career in 1983 with Drackett Company, where he served as director of such products as Windex(TM), Endust(TM), Vanish(TM), and Renuzit(TM). Under his leadership, Drackett secured patents for sodium chlorite-based odor elimination, oxidation chemistry, and the invention of the Vanish(TM) Drop-ins automatic toilet bowl cleaner. When SC Johnson acquired Drackett in 1992, Hutchings remained and advanced through a series of senior roles including service on the acquisition team for Dow Brands and subsequently as global head of research, development and engineering for the launch of both the Glade(TM) Liquid Electric Air Freshener and Oust(TM) Odor Eliminator, before becoming SC Johnson's global Chief Technical Officer.
Hutchings holds a bachelor's degree in chemistry and physics from Mercer University and a PhD in physical chemistry from the University of Tennessee, Knoxville, where his thesis work focused on solution thermodynamics. He has served on several SC Johnson corporate boards throughout the world.
In the coming weeks, Fuse Science expects to formally introduce the first in a series of innovative performance products for aspiring athletes and energy seekers under the "EnerJel" brand. EnerJel showcases the first all natural, trans-dermal technology to address high performance muscle fatigue so athletes can perform at their natural best with more rapid results.
Tuffin also reported that the company has recently completed a series of product endorsement contracts with some of professional sports' most notable athletes, and expects to announce these in conjunction with the formal launch of the company's products in the coming weeks.
"Fuse Science has been deliberately patient in our efforts to execute on all facets of our strategic plan," added Tuffin. "We are building shareholder value each step of the way and will continue to develop the foundation so that the company is built for long-term, sustainable growth."
About Double Eagle Holdings
Double Eagle Holdings (Pink Sheets: DEGH) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).
Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.
Media Contact:Liza M Santana305.968.2384lmsantana@creativasgroup.com
SOURCE Double Eagle Holdings, Ltd.
lol thanks I am new to all of this info. But, realistically how high do you think this stock can go?
Who are in charge of setting up the bids /ask for the company? How is this regulated?
What does "L2" mean?
What is PSPW & PFMS
Hey I agree with you guys but I am new to this so I am also waiting it out with you guys. Hey you all have been doing this for a while. Is it me or is this really big news for a team like this to be put together while still a penny stock?
what is a reverese merger run?
What is a "bagger"?
ok ulfahl thanks for the info your know ya stuff!!
Hey guys,
How do a company go from being a pink sheet to trading on a major stock excange?
New trials posted as early as tomorrow morning at 10am?
I heard there will be a major announcement from Advaxis Incorporated in regards to their advancement of their Phase II cervical cancer vaccine data which is supposed to be extremily positive as early as tomorrow morning at 10:00am I am very excited about this!! Does anyone know more about the details? Please enlighten me.
THE BEST STOCK OUT! EVERYONE SHOULD READ!!
I hope everyone is ready (including bashers).... because I'm about to drop some serious knowledge on your a$$. The following are points I highlight when convincing friends and family to invest in ADXS.
1) Phase I had 15 people in it, all with stage 4b cervical cancer (VERY SICK PEOPLE). They all received 2 doses of the vaccine when it was known that 3 doses is the actual therapeutic dose. Why only 2? Because the company was scared. This had never been tested on humans before. Still.... with just 2 doses, 3 of these patients lived 3 years and 2 are still living 4 years out! The historical median survival is 6 months! This trial had a median survival of close to 1 year! Imagine the results when 3 doses are given AND given in combination with chemo!!!
2) Provenge extends life an average of 4 months, is difficult to administer, and will cost Medicare $93,000. Yet it was approved!! And for just 4 extra months of life!! Listeria based vaccines are easy to produce, easy to administer, potentially very efficacious, and will cost Medicare 15x (at least) less for reimbursement.
3) Drugs fail to be FDA approved because they are dangerous. We know 72 patients...sick patients... have received the vaccine and no serious side effects were experienced.
4) Provenge is a one trick pony. There are NINE Listeria constructs and who knows how many more cancers this can be applied to? The possibilities are literally infinite. Insert any antigen you desire. The vector (Listeria) will work the same way and elicit the same immune response. This could prove disasterous however if the technology DOESN'T work since one construct will give a glimpse into all the others. Please see point 1 for hints that it DOES work.
5) ADXS management is brilliant. They have a phase 2 going on in CIN (pre-cervical cancer) AND Stage 4b cervical cancer. If it works in both, chances are this vaccine will be approved for ALL stages of cervical cancer. Provenge is only approved for late stage/metastatic prostate cancer.
6) ADXS has collaborative agreements with NCI, CRUK, Dept of Homeland Security, Wister, etc. NCI and CRUK are running trials at their OWN EXPENSE. Organizations of this caliber do not associate with POS companies.
7) Veterinary applications. If this thing ONLY works in cattle to prevent hoof and mouth disease we are looking at a $10 stock. Forget humans. There are millions of cattle worldwide and they are a commodity. Let's not forget about canine osteosarcoma as well.
8) A lesson in pattern recognition. DNDN went as high as $54 and was the first immunotherapy approved. How high will the next approved immunotherapy go? No telling how high ADXS goes with 9 constructs and limitless constructs in the future. Imagine the kind of profit you can make by buying in NOW! And trust me... the cost effectiveness of Listeria based vaccines is a HUGE issue. Let's say ADXS vaccines extend life of prostate cancer patients 3 months and Provenge extends it 4 months. Guess which one will be reimbursed by Medicare. NOT Provenge. Why? Because 1 month of life is not worth an extra $90,000 to the government.
9) Great business model. ADXS has never had a problem raising money. There is minimal dilution. And guess what? They have enough to make it to the end of phase 2. Forget phase 3. After good phase 2 results they license out the technology and collect big time!! Why is this good? Because it means the share price will move FAST and you won't have to wait very long before you are a millionaire.
10) Advaxis has the only immunotherapy that downregulates T-regs. These T-reg cells help protect the tumor from immune attack. No other immune therapy dose this. And this is a big reason why Advaxis vaccines will work.
Keep this post at the top for newbies and feel free to add.
EVERYONE SHOULD READ AND SPREAD THE WORD!!
I hope everyone is ready (including bashers).... because I'm about to drop some serious knowledge on your a$$. The following are points I highlight when convincing friends and family to invest in ADXS.
1) Phase I had 15 people in it, all with stage 4b cervical cancer (VERY SICK PEOPLE). They all received 2 doses of the vaccine when it was known that 3 doses is the actual therapeutic dose. Why only 2? Because the company was scared. This had never been tested on humans before. Still.... with just 2 doses, 3 of these patients lived 3 years and 2 are still living 4 years out! The historical median survival is 6 months! This trial had a median survival of close to 1 year! Imagine the results when 3 doses are given AND given in combination with chemo!!!
2) Provenge extends life an average of 4 months, is difficult to administer, and will cost Medicare $93,000. Yet it was approved!! And for just 4 extra months of life!! Listeria based vaccines are easy to produce, easy to administer, potentially very efficacious, and will cost Medicare 15x (at least) less for reimbursement.
3) Drugs fail to be FDA approved because they are dangerous. We know 72 patients...sick patients... have received the vaccine and no serious side effects were experienced.
4) Provenge is a one trick pony. There are NINE Listeria constructs and who knows how many more cancers this can be applied to? The possibilities are literally infinite. Insert any antigen you desire. The vector (Listeria) will work the same way and elicit the same immune response. This could prove disasterous however if the technology DOESN'T work since one construct will give a glimpse into all the others. Please see point 1 for hints that it DOES work.
5) ADXS management is brilliant. They have a phase 2 going on in CIN (pre-cervical cancer) AND Stage 4b cervical cancer. If it works in both, chances are this vaccine will be approved for ALL stages of cervical cancer. Provenge is only approved for late stage/metastatic prostate cancer.
6) ADXS has collaborative agreements with NCI, CRUK, Dept of Homeland Security, Wister, etc. NCI and CRUK are running trials at their OWN EXPENSE. Organizations of this caliber do not associate with POS companies.
7) Veterinary applications. If this thing ONLY works in cattle to prevent hoof and mouth disease we are looking at a $10 stock. Forget humans. There are millions of cattle worldwide and they are a commodity. Let's not forget about canine osteosarcoma as well.
8) A lesson in pattern recognition. DNDN went as high as $54 and was the first immunotherapy approved. How high will the next approved immunotherapy go? No telling how high ADXS goes with 9 constructs and limitless constructs in the future. Imagine the kind of profit you can make by buying in NOW! And trust me... the cost effectiveness of Listeria based vaccines is a HUGE issue. Let's say ADXS vaccines extend life of prostate cancer patients 3 months and Provenge extends it 4 months. Guess which one will be reimbursed by Medicare. NOT Provenge. Why? Because 1 month of life is not worth an extra $90,000 to the government.
9) Great business model. ADXS has never had a problem raising money. There is minimal dilution. And guess what? They have enough to make it to the end of phase 2. Forget phase 3. After good phase 2 results they license out the technology and collect big time!! Why is this good? Because it means the share price will move FAST and you won't have to wait very long before you are a millionaire.
10) Advaxis has the only immunotherapy that downregulates T-regs. These T-reg cells help protect the tumor from immune attack. No other immune therapy dose this. And this is a big reason why Advaxis vaccines will work.
Keep this post at the top for newbies and feel free to add.